New warnings have been added to the safety labels of the type 2 diabetes drug Gylxambi, the Food and Drug Administration (FDA) announced. Gylxambi is a combination of the diabetes drugs empagliflozin and linagliptin. Emphagliflozin is the active ingredient in the diabetes treatment Jardiance, which is in a class called SGLT2 inhibitors. Other drugs in this class include Invokana and Invokamet. Last year, the FDA required all SGLT2 inhibitors to include new warnings for serious urinary tract infections in patients taking the drugs, as well as an increased risk of ketoacidosis, a condition in which too much acid builds up ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.